0001615774-18-009357.txt : 20180907 0001615774-18-009357.hdr.sgml : 20180907 20180907160819 ACCESSION NUMBER: 0001615774-18-009357 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180905 FILED AS OF DATE: 20180907 DATE AS OF CHANGE: 20180907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: OLUKOTUN ADEOYE Y CENTRAL INDEX KEY: 0001242615 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 181060247 MAIL ADDRESS: STREET 1: 3621 SOUTH STATE ST STREET 2: 695 KMS PL CITY: ANN ARBOR STATE: MI ZIP: 48108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 1-800-849-7894 MAIL ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 4 1 s112616_form4.xml 4 X0306 4 2018-09-05 0 0001430306 Tonix Pharmaceuticals Holding Corp. TNXP 0001242615 OLUKOTUN ADEOYE Y C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVENUE,SUITE 306 NEW YORK NY 10022 1 0 0 0 Stock Option 1.03 2018-09-05 4 A 0 15000 0.00 A 2028-09-05 Common Stock 15000 15000 D The option was granted on September 5, 2018 pursuant to the Issuer's 2018 Equity Incentive Plan and vests on the date of the Issuer's 2019 annual meeting of shareholders. /s/ Jessica Morris, Attorney-in-Fact 2018-09-07 EX-24.1 2 s112616_ex24-1.htm EXHIBIT 24.1

Exhibit 24.1

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby constitutes and appoints each of Bradley Saenger and Jessica Morris, or either of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer or director or both of Tonix Pharmaceuticals Holding Corp. (the "Company"), Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder;

2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and

3. take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 7th day of September, 2018.

Signed and acknowledged:

Signature: /s/ Adeoye Olukotun

Name: Adeoye Olukotun, M.D.